Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unfortunately, is not only that. After diluting shareholders to death and destroying all of the company Market Value, he changed his more than 37 million warrants post RS for free shares. He should have paid US$0.5 per share according to the agreements (that is US$18.5 million), but paid NOTHING and now owns around 50% of the OS. What a crook.
And he made it look like it was for the benefit of the company as you can all see below from the 8-K filing. Shameless crook. That is so dishonest. He is the board of directors, so he made a new agreement with himself to change his warrants for free shares. It would be great to hear an opinion from a lawyer about the legality of this.
https://www.otcmarkets.com/filing/html?id=14277338&guid=lZbKUq2e-NCnp3h
Full disclosure, I own shares of XDSL and of his other company and I think he is going to do the same there. Don't know what I'm going to do.
Agreed Crozz, even with all the anger I feel for Anshu the liar, I think you are absolutely right. I hope that what you are saying happens and we all can sell soon enough recovering at least part of our losses. I also think a lot or all of the convertible notes were converted with the endless dilution before the RS, but he sold a new one for $88K on Jan 13th. Hope we don't see that one convert.
Definitely after Anshu showed his true colors, I now think this is a stock to trade but not get in love with as I unfortunately did before.
Thanks shots60 for your kind words. The same goes to you. I know the excellent person you are through all of our interactions. Good luck to you in all of your investments. Let's keep in touch and hope to recover at least some of our losses.
Thanks a lot my friend!!! Good luck to you also!!
Good to know that you could make it back into the green my friend. I sold the majority of my shares for a huge loss. Agree 100% with what you say in your post.
Thanks a lot Justjoe1979 for your words.
Me too, Debo82.
I would agree Coachshot99, thanks for asking. That was when I thought Anshu was telling the truth.
Thanks woodleighinvestor, appreciate your words. Agree with you, not sure if they will become defunct, but I think they will continue falling as you mentioned and who knows if that will change some day with the dishonest way Anshu acts.
Thanks a lot Axolotl for your words!!!
Thanks a lot Axolotl for your words!!!
Thanks JOHNNY-VEGAS for your kind words and wishes. Yes, you were right.
Hope you do well also!!
Thanks Charlye, I hope that works for you.
Most of them Charlye at a huge loss and keeping a few.
Yes, another 8-K filed Yesterday. Unfortunately another toxic convertible note (40% discount to previous 15 trading days minimum price).
https://www.otcmarkets.com/filing/html?id=14637781&guid=0mJKUpikzTELk3h
Thanks a lot Handmanw for sharing, what a great post.
Totally agree with you Sojourner55. Take a look at this link to my post with the supporting information of why I strongly beleive that is the case.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160927040
Totally agree with you TiltMyBrain. Please take a look at this link to my post with the supporting information of why I think that and let me know your comments.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160927040
tanman42, to be honest I don't know, but I asked my ex-wife, who is a recognized hematologist and had participated in investigations and journal publications, and she told me minimum 2 to 3 months. She was the one to tell me about stringent journal restrictions regarding preliminary media press releases and that's why I did some DD on that, looked for the ICMJE guidelines and shared them here.
Totally agree about the journal article trocprofit. See this link to my post with the corresponding supporting information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160927040
Not only them. I think the company doesn't want to risk journal publication. See this link to my post regarding what I think about it and the corresponding supporting information. Please let me know your thoughts on that.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160927040
Thanks highwayman4life, excellent post and agrees 100% with what I found in the ICMJE (International Committee of Medical Journal Editors) site. Take a look at the following link to my post with the corresponding details:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160927040
You're very welcome Astavakra and thank you for your kind words.
Let me offer a third possible positive explanation for the Delay in TLD. I strongly believe this is the reason.
3. Company looking for acceptance and as high as possible priority of a publication in a prestigious medical journal, which take a long time taking into account revisions, corrections, experts peer reviews, etc. that can only start after staticians work is finished. In order to be successful, the most important goal for a pharmaceutical company finishing a Phase III trial is to spread the message to the medical community and in a professional way and not to just give information to investors and general public. All recognized journals have restrictions about the use of media and press releases. If the company just publishes TLD as soon as possible without any strategy, publication may be not approved or not prioritized by a prestigious journal.
I also strongly believe that trial outcome is positive, because otherwise the company would not be so interested in getting the journal publication and they would be at risk of having legal consequences for not reporting earlier if results were bad.
Below are some extracts of the document Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated December 2019) published by the International Committee of Medical Journal Editors (ICMJE) that support what I'm mentioning. Take a look at the whole document if you like, to these extracts, or to what is in bold, specially red bold.
Link to the document mentioned: http://www.icmje.org/icmje-recommendations.pdf
Also take a look at the amount and prestigious names (NEJM and the Lancet among much others) of journals that follow ICMJE. They provide a list. Link to ICMJE webpage: http://www.icmje.org/
I also think that juornal publication is the reason for not having new end point information updated with the FDA (clinicaltrials,gov information is updated by the company) and having it updated in the UK and Germany (information is not updated by the company, but by the regulatory entities). Look at the extracts of the document where it mentions government agencies.
Skitahoe, in the following link you can see my thoughts about this and the supporting documents:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160901417
Both, NEJM and the Lancet, follow ICMJE as most or all of the prestigious journals.
What about this one:
Company looking for acceptance and as high as possible priority for a publication in a prestigious journal for the medical community. You mentioned in a previous post that they don't need journal acceptance to release basic TLD and I agree with that, but the opposite could happen. If the company just publishes TLD as soon as possible without any strategy, publication may be not approved or not prioritized by a prestigious journal.
I also think that it is the reason for not having new end point information updated with the FDA (clinicaltrials,gov information is updated by the company) and having it updated in the UK and Germany (information is not updated by the company, but by the regulatory entities). Look at the extracts of the document where it mentions government agencies.
I also strongly believe that trial outcome is positive, because otherwise the company would not be so interested in getting the journal publication and they would be at risk of having legal consequences for not reporting earlier if results were bad.
Below are some extracts of the document Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated December 2019) published by the International Committee of Medical Journal Editors (ICMJE) that support what I'm mentioning. Take a look at the whole document if you like, to these extracts, or to what is in bold, specially red bold.
Link to the document mentioned: http://www.icmje.org/icmje-recommendations.pdf
Also take a look at the amount and names of journals that follow ICMJE. Link to ICMJE webpage: http://www.icmje.org/
You're very welcome StonkMaster and thank you for your comments.
I want to share what I found in the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals document (updated December 2019) published by the International Committee of Medical Journal Editors (ICMJE).
I strongly believe that the reason for the delay in the press release with TLD is clear and is related to the journal publication approval restrictions and prioritization. I think that it also is the reason for not having clinicaltrials,gov updated with the new end points, where information is updated by the company, and having it updated in UK and Germany, where it is not updated by the company, but by the regulatory entities. I also strongly believe that trial outcome is positive, because otherwise the company would not be so interested in getting the journal publication and they would have legal consequences for not reporting earlier.
Link to ICMJE webpage: http://www.icmje.org/
Link to the document: http://www.icmje.org/icmje-recommendations.pdf
Below are some extracts of this document, where I highlighted the statements that support what I'm mentioning:
According to Evaluate's post Yesterday, the answer he received from SITC is that they will also have a poster:
Thanks Mortimerduke!!
Totally agree. And in this case if they cancel Tomorrow they would be canceling one working day before SITC starts, which is even worse. They canceled SNO more than 2 weeks before it starts. If they were planning to cancel both, they would have canceled SITC before or at least at the same time with SNO. Also, I insist in what I mentioned in my post from Yesterday that they had the same title for the presentation in both SNO and SITC (“Phase III Clinical Trial to Test the Safety and Efficacy of Autologous Tumor Lysate-Loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma”). So I would expect them planning the same presentation material in both:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159304505
This reinforces the theory of them having SNO option in case they didn't have everything ready for SITC.
And one last thing, company's participation is SITC was shared by one poster of this board (I think it was Sojo) long time after SNO participation was discovered. Just a few days ago (this week I think). So I would expect that participation in SITC was decided by the company after and I don't think they did that to then cancel a few days later in the same week. Doesn't make any sense.
Disclaimer: In case you find mistakes in my writing, English is not my native Language.
I think we will know before opening. My opinion is that Bid and Ask will start to continually move up before 9.30 AM and we will gap up.
Thanks Whitewater55.
One thing I disagree is that if the presentation title for both SITC 2020 and SNO 2020 conferences is the same:
“Phase III Clinical Trial to Test the Safety and Efficacy of Autologous Tumor Lysate-Loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma”
I would expect the same content in both conferences. So if TLD is to be announced before SNO, which I think is the case, I would expect it being announced before SITC, so on November 9th premarket at the latest, that is when the poster will be available.
Disclaimer: English is not my native Language.
Agree 100%.
Right MasterBlastr, and also remember ATLnsider’s post 315347, where he shared the information about the new endpoints of the trial. There is also stated that the EU clinical trial register will evaluate those end points in October 2020. How could they evaluate them without TLD?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158783215
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/GB#summary
P.D. English is not my primary language.
I think they will release without warning.
Thanks ATLnsider
ATLnsider, do you think that this change could be related to results received by EU Clinical Trials Register?
That is not true, they both show OS as primary end point, and most importantly, comparable to contemporaneous trials who received standard of care therapy only:
I strongly believe VRUS is coming to an end of dilution and share price is going to correct in an explosive way (minimum 10 X).
Following is a Table with my estimation of the situation of all notes and convertible notes as of September 30th. I have put it together by looking at VRUS historical filings and crossing information from them. Amounts in $ US:
Also, below is a chart with the summary of that information for convertible notes.
* Increases in convertible debt amounts are shown in red, reductions in green and amounts as of the end of each quarter, in blue.
Very important to note the dramatic decrease in convertible notes $ Dollar amount in the last less than 2 quarters, having them almost done. All this, after it was increasing or stable for the last 5 quarters before that. For the first time, starting on Q3 2020, convertible notes amount is decreasing and by the incredible amount of $1.536 million from the maximum of $2.007 million as of April 30th 2020, to $0.471 million as of Sept. 30th 2020. That is a 77% decrease and much more rapid than the way it increased (less than 2 quarters decreasing vs. 5 quarters increasing).
Anyone that doubts about this, can also take a look at the much lower volume for the last days and how price has been sustaining. Additionally to that, remember that White Lion is also done for now, as announced by the company.
We are tremendously undervalued. Easily a 10X bagger being conservative. 12 months trailing revenue of $20+ million with a 4 times multiplier gives a share price of around 0.02 with just the business we have. And businesses are valued according to forward revenues (not trailing revenues) which will be much higher.
Expected news coming shortly about new customers, TJ Maxx / Marshal's / Meijer / Bog 5 orders, NHL startup, other leagues agreements, CBD, peanut butter new product, middle east business, commercial lines of credit attached to Libor or any surprise as the ones they like to give us when we least expect, will just make the situation much better.
To close, I want to repeat that some people forget what happened to businesses around the world with Covid. And that VRUS is not only surviving, but doing incredible improvements.